Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Files An 8-K Shareholder Director Nominations
Item 5.08 Shareholder Director Nominations
The Board of Directors of Protalix BioTherapeutics, Inc. (the
Company) has approved the record date for the Companys 2017
Annual Meeting of Stockholders (the Annual Meeting) to be held on
or about April 10, 2017. Holders of the Companys common stock at
the close of business on March 15, 2017, the record date, will be
entitled to receive notice of, and to vote at, the Annual
Meeting. The final date and time of the meeting will be announced
in the proxy statement to be filed and distributed by the Company
in connection with the Annual Meeting.
In order for a proposal to be considered timely, it must be
received by the Company on or prior to March 2, 2017 at its
principal executive offices at 2 Snunit Street, Science Park,
P.O. Box 455, Carmiel 20100, Israel. Proposals should be directed
to the attention of the Secretary.
The Company plans to file with the Securities and Exchange
Commission (the SEC), and mail to its Stockholders a proxy
statement in connection with the Annual Meeting, and advises its
stockholders to read the proxy statement relating to the Annual
Meeting when it becomes available, as it will contain important
information. Stockholders may obtain a free copy of the proxy
statement and any other relevant documents (when available) that
the Company files with the SEC via the SECs web site at
www.sec.gov. The proxy statement and these other documents, when
available, may also be obtained free of charge from the Company
by directing a request to the Company at 2 Snunit Street, Science
Park, P.O. Box 455, Carmiel 20100, Israel, Attention: Secretary.
The Company, its directors and named executive officers may be
deemed to be participants in the solicitation of the Companys
stockholders in connection with the Annual Meeting. Stockholders
will be able to obtain information regarding the names,
affiliations and interests of such individuals in the Companys
Annual Report on Form 10-K for the year ended December 31, 2016,
and in the other filings by the Company with the SEC.
Item 9.01. Financial Statements and Exhibits
| (d) | Exhibits |
| 99.1 | Press release dated February 14, 2017. |
About Protalix BioTherapeutics, Inc. (NYSEMKT:PLX)
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company’s product pipeline includes PRX-102 for the treatment of Fabry disease; AIR DNase (PRX-110) for Cystic Fibrosis, and Oral Anti-TNF (OPRX-106) Anti Inflammatory. PRX-102 or alpha-GAL-A is an enzyme replacement therapy product for the treatment of Fabry disease. AIR DNase is a plant cell recombinant human Deoxyribonuclease 1. Oral Anti-TNF represents a mode of administering a recombinant anti-TNF protein. Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Recent Trading Information
Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) closed its last trading session down -0.06 at 1.25 with 7,330,781 shares trading hands.
